Jan 27 2026
Animal research demonstrated that prenatal exposure to CBD protected offspring of obese mothers from brain inflammation and neurodevelopmental impairments, pointing to possible preventative benefits that warrant further human studies.
Researchers found that cannabis use was associated with reduced inflammation in individuals with HIV or methamphetamine use disorder. The findings suggest potential benefits for immune health, though further controlled studies are needed.
A clinical trial indicated that CBD supplementation may reduce systolic blood pressure in adults, pointing to its possible role in cardiovascular health management. Researchers note the need for larger, longer-term trials.
An analysis showed that heavy alcohol consumption was linked to higher rates of unintended pregnancy, while heavy cannabis use was not significantly associated. The study underscores alcohol’s stronger role in reproductive health risks.
Clinical findings revealed that cannabinoid-based medicines improved several inflammatory markers in people living with HIV, suggesting potential therapeutic benefits in immune regulation and long-term health outcomes.
In a PDAC mouse model, CBD monotherapy extended survival while THC alone or the combo did not; benefits were linked to shifts in gut microbiota and bile acid metabolism, pointing to potential biomarkers and a therapeutic angle.
An open-label, six-week pilot (n=12) using 30 mg/day full-spectrum sublingual CBD reported notable anxiety reduction with improvements in sleep and quality of life, no serious adverse events, and a call for larger placebo-controlled trials.
Review of cannabinoids, terpenes, and other Cannabis sativa constituents suggests possible roles in blocking viral entry and tempering cytokine-driven inflammation (e.g., via CB2/PPARγ), while emphasizing the need for rigorous clinical validation and better bioavailability.
Patient-reported outcomes (n=751) over six months showed clinically meaningful improvements in CIPN symptoms; THC-dominant regimens particularly helped burning/cold sensations, and THC/CBD interaction correlated with greater quality-of-life gains.
A study from the University of Haifa found that in Alzheimer’s-model rats, chronic CBD reversed memory decline and reduced inflammation and Alzheimer’s-related brain pathology (amyloid plaques, tau) largely via CB1 receptor activation.
In a controlled lab experiment involving people who regularly use both alcohol and cannabis, using cannabis before drinking reduced the number of alcoholic drinks consumed and lowered cravings in a subset of participants (“substituters”).
Patients with insomnia who used medical marijuana reported better sleep quality and reduced anxiety symptoms over the study period.
In cell-based experiments, CBD enhanced the anti-cancer effects of EGFR inhibitors in oral cancer lines by suppressing resistance mechanisms and promoting cancer cell death.
Researchers discovered that several cannabinoids—including CBD and CBG—disrupted MRSA biofilms and significantly reduced bacterial viability, even against stubborn, drug-resistant strains. The cannabinoids also suppressed expression of key resistance genes, pointing to their potential as novel anti-biofilm therapies.
Scientists have developed a reliable DNA marker applicable across diverse cannabis varieties, enabling sex determination in seedlings. This breakthrough offers a practical, accurate alternative to labor-intensive early flowering methods and promises major efficiencies for growers.
A national survey revealed that approximately 8% of cancer survivors currently use marijuana, with almost half doing so specifically for symptom relief—including pain, nausea, anxiety, and sleep—with many noting improvements.
Analysis of crash data before and after marijuana legalization in Connecticut showed no meaningful increase in traffic accidents or fatal crashes, suggesting that legalization did not adversely impact road safety in that context.
In comparative pharmacokinetic studies, CBDA—cannabidiolic acid—demonstrated markedly higher absorption and stability than CBD across both animal models and cell cultures, positioning it as a potentially more efficient therapeutic cannabinoid.
Researchers developed polyvinyl alcohol (PVA) hydrogels infused with THC and either propylene glycol or vegetable glycerin to enhance skin delivery. These hydrogels maintained structural stability, supported skin cell growth, and released THC gradually over several days, offering a safe, controlled-release system potentially useful for treating localized inflammation.
Scientists developed folic acid–modified chitosan nanoparticles carrying CBD, which outperformed free CBD against triple-negative breast cancer cell models. The nanoparticles enhanced CBD absorption, increased reactive oxygen species, triggered cancer cell death, and achieved a remarkable 68% tumor reduction in animal models with minimal toxicity.
Using neuroimaging in rats, researchers found THC increased overall brain connectivity and blood flow, while CBD decreased connectivity without affecting blood flow. When combined, they produced moderate, balanced effects—suggesting CBD may temper some of THC’s brain stimulation, a finding that could guide targeted cannabinoid therapies.
In a proof-of-concept pilot with one participant, inhaled cannabis administered before naloxone reduced withdrawal severity (as measured by COWS scores) without increasing cardiovascular risk. These preliminary results hint at cannabinoids’ potential role in mitigating detox-related discomfort during opioid reversal.
In a rat model of hepatic encephalopathy, combined treatment with CBD and low-dose radiation improved liver and brain outcomes by reducing oxidative stress, inflammation, and cognitive decline—outperforming either modality alone, and suggesting a synergistic therapeutic strategy.
A study in the Journal of Cannabis Research uncovered previously overlooked compounds—specifically neolignans like dadahol A and B—in hemp roots that exhibit potent cytotoxic effects against pediatric cancer cell lines, particularly neuroblastoma. Dadahol A showed especially low inhibitory concentrations, highlighting hemp roots as a promising new source for anti-cancer drug discovery.
A case study published in Frontiers in Psychiatry documented a 28-year-old man with Tourette syndrome and ADHD who used up to 10 grams of inhaled medical cannabis daily and was still deemed fit to drive according to German standards. Remarkably, driving ability remained intact even at high THC serum levels, accompanied by improved tics, attention, and sleep.
A chemical investigation revealed previously undocumented flavoalkaloid compounds in cannabis leaves, expanding the known chemical diversity of the plant and suggesting potential new bioactive targets for future therapeutic research.
This study demonstrated that CBG significantly reduces liver fibrosis in preclinical models by lowering fat accumulation and inflammatory markers in the liver, pointing to its promise as a candidate for treating metabolic liver disease.
A survey of Dutch patients with brain tumors found that more than 50% have used cannabis, primarily to ease symptoms like pain, insomnia, and anxiety—highlighting the role of cannabis as a commonly embraced complementary therapy in oncology.
Researchers conducting controlled cognitive tests found minimal difference between men and women in short-term effects of cannabis on memory, attention, and processing speed—suggesting similar cognitive impacts across sexes under acute use.
Preclinical results show that when combined with standard antibiotics, CBD enhances bacterial killing against highly resistant A. baumannii strains—offering a potential adjuvant strategy to bolster treatment efficacy in serious, drug-resistant infections.
In a blinded crossover trial involving 54 dogs, only the combination of 2 mg/kg CBD with L-tryptophan and α-casozepine significantly lowered cortisol levels following a stress-inducing car ride, suggesting this blend may help reduce acute travel-related stress, though results varied by breed and individual CBD absorption.
A systematic review of 16 studies covering nearly 8,850 women found strong evidence that cannabis improves orgasm frequency, ease, intensity, satisfaction, and overall sexual function. Benefits were more pronounced with frequent, low-to-moderate dosing before sexual activity, though occasional focus issues were noted.
